Harmony Biosciences Holdings (HRMY) Net Cash Flow (2019 - 2026)

Harmony Biosciences Holdings' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$163.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 553.1% year-over-year to -$163.1 million; the TTM figure through Mar 2026 stood at $100.4 million (down 35.65% YoY), while the FY2025 annual figure was $299.5 million, up 111.9% from the prior year.
• Net Cash Flow came in at -$163.1 million for Q1 2026 at Harmony Biosciences Holdings, down from $105.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $105.5 million in Q4 2025 to a low of -$163.1 million in Q1 2026.
• A 5-year average of $20.9 million and a median of $24.8 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 874.83% in 2024 and plunged 553.1% in 2026, its largest moves.
• Harmony Biosciences Holdings' Net Cash Flow stood at -$17.6 million in 2022, then grew by 26.4% to -$12.9 million in 2023, then surged by 607.89% to $65.6 million in 2024, then jumped by 60.74% to $105.5 million in 2025, then sank by 254.6% to -$163.1 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$163.1 million, $105.5 million, and $100.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison